Alterity Therapeutics Ltd has released a press release.
Meeting with US FDA provides development path for ATH434
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Presentation on ATH434 to American Academy of Neurology
- Appendix 4C and Quarterly Update
- NASDAQ Temporary Relief
- NASDAQ Non-Compliance Notice Received
- Appendix 4C - quarterly
Later from Alterity Therapeutics
- Pause in Trading
- New data independently confirms safety profile of ATH434
- Preliminary Final Report
- Company update on Annual Report 2020
- Alterity raises $35M in placement to institutional investors
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics